• Study Establishes ENPP1 As A Biomarker For Immunotherapy Benefit

    Clinical Research News | Researchers in California have shown that breast cancer patients with RNA expression levels of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) in the bottom 50th percentile can confidently be treated with Keytruda (pembrolizumab) as well as surgery.

    Mar 7, 2024

  • Five Health Systems Picking Dandelion Health To Advance Clinical AI

    Clinical Research News | If artificial intelligence (AI) is to be as insightful as possible in advancing human health, it is not enough to have a patchwork of out-of-context data from which to draw conclusions. That is unfortunately the current situation and at the cost of lost opportunities to better treat patients, identify early biomarkers of disease, and recognize the right endpoints in clinical trials—not to mention eradicating existing biases against marginalized groups of people.

    Mar 6, 2024

  • Future Looks Bright For Decentralized Clinical Trials

    Clinical Research News | Decentralized clinical trials (DCTs) today are both more fit-for-purpose and business-as-usual than uncertain and unavoidable, as was the case during the height of the COVID-19 pandemic. Among the key challenges with DCTs are keeping sites and patients engaged, dealing with the near-constant inflow of data from digital platforms and wearable devices, and quantifying the value of various decentralized study components.

    Mar 5, 2024

  • Medidata Collaboration to Deploy Vaccine Studies, New CEO at Saama, H1 Updates to AI Toolkit, More

    Clinical Research News | Medidata and Sanofi Vaccines announced a collaboration to harness Medidata eCOA to deploy in vaccine studies; H1 has launched GenosAI Pro, a new addition to its conversational AI toolkit within Trial Landscape platform; and more.

    Feb 29, 2024

  • Follow the Money: First Circular RNA-Based Clinical Assay, Oncology Programs, More

    Clinical Research News | Circular Genomics plans to build and scale commercial operations in preparation for the launch of the world's first circular RNA-based clinical assay; NextPoint Therapeutics will advance the company’s two immuno-oncology clinical programs, NPX267 and NPX887; Accent Therapeutics will use funding to support the advancement of both lead programs—Accent’s first-in-class DHX9 inhibitor and a potentially best-in-class KIF18A inhibitor; and more.

    Feb 28, 2024

  • CliniSpan Health Wins SCOPE’s Clinical Trial Tech: Startup Pitch Contest

    Clinical Research News | If artificial intelligence (AI) is to be as insightful as possible in advancing human health, it is not enough to have a patchwork of out-of-context data from which to draw conclusions. That is unfortunately the current situation and at the cost of lost opportunities to better treat patients, identify early biomarkers of disease, and recognize the right endpoints in clinical trials—not to mention eradicating existing biases against marginalized groups of people.

    Feb 27, 2024

  • Convergence of Clinical Research and Clinical Care On The Horizon

    Clinical Research News | If artificial intelligence (AI) is to be as insightful as possible in advancing human health, it is not enough to have a patchwork of out-of-context data from which to draw conclusions. That is unfortunately the current situation and at the cost of lost opportunities to better treat patients, identify early biomarkers of disease, and recognize the right endpoints in clinical trials—not to mention eradicating existing biases against marginalized groups of people.

    Feb 27, 2024

  • ClinEco Commons Launches, Offering Portal for Industry Resources, Expertise

    Clinical Research News | At SCOPE last week, ClinEco launched ClinEco Commons, the latest addition to the growing online community and marketplace designed to be the central resource for clinical research professionals worldwide, offering a comprehensive and easy-to-use portal for critical information and industry expertise.

    Feb 23, 2024

  • Next Level Supply Chain Optimization: A Strategic Approach to Managing Clinical Trial Costs

    Clinical Research News | Clinical trials have experienced tremendous innovation in the last few years. The introduction of new technologies such as wearable devices, machine learning, remote monitoring, and virtual clinical visits holds tremendous promise to expedite therapeutics to market and reduce the cost of clinical trials.

    Feb 23, 2024

  • Clinical Trial Tech – What Investors Want And Studies Need

    Clinical Research News | The perspectives of clinical trial technology investors and trends for future investment were the topics of a pair of fast-paced panel discussions at last week’s Summit for Clinical Ops Professionals (SCOPE) in Orlando. What investors want appears to be well aligned with what sponsors and sites say they need—solutions running the gamut from better matching patients to trials and improving access to streamlining the way studies get designed and conducted.

    Feb 20, 2024

  • SCOPE Summit 2024 Award Winners

    Clinical Research News | SCOPE Summit 2024 once again shined a spotlight on the breakthroughs, discoveries, and achievements of hundreds of organizations in their efforts to improve clinical trials and help patients worldwide. Three awards were presented at the conference: the Participant Engagement Award, the Site Innovation Award, and the Best of Show Award.

    Feb 15, 2024

  • Pharmaceutical Targets Identified For Osteoarthritis

    Clinical Research News | Researchers from the University of Adelaide (Australia) and the Columbia University (New York) have “reimagined” osteoarthritis, providing a pharmaceutical target for the discovery of drugs to reverse and treat the ubiquitous degenerative joint disease. Osteoarthritis was originally believed to be a “wear and tear” condition, and some people still refer to it that way, which wrongly implies that its progression is a matter of time and inevitable.

    Feb 13, 2024

  • New Products, Company News On Display at SCOPE

    Clinical Research News | The days leading up to the Summit for Clinical Ops Professionals—SCOPE—are a busy time for the clinical trials and clinical research space. The event kicked off yesterday and so far we’ve gathered these company and product news.

    Feb 12, 2024

  • New Patient Scoring Method To Enable Precision Medicine For Chronic Diseases

    Clinical Research News | In a big advance for precision medicine, researchers in Australia have developed a genetic biomarker of people’s response to sodium reduction. It is often but not always the case that modifying sodium levels lowers blood pressure by reducing the fluid volume of blood in the cardiovascular system, and knowing in advance how patients will respond could help eliminate the “treatment odyssey” that many of them are experiencing.

    Feb 8, 2024

  • Best of Show Finalists Named for SCOPE 2024

    Clinical Research News | Dozens of companies are showcasing new products at next week’s Summit for Clinical Ops Executives, and 37 have been named finalists in the Best of Show People’s Choice Awards. The SCOPE community is invited to identify exceptional innovation in technologies used by life science professionals, voting on the most impactful new products of the year. Winners will be announced at the event on Tuesday, February 13.

    Feb 7, 2024

  • Two-In-One Cholesterol-Lowering Vaccine Now Ready For Clinical Testing

    Clinical Research News | Investigators with The University of New Mexico (UNM) and the National Institutes of Health (NIH) have succeeded in developing a cholesterol-lowering vaccine that works independently of statins. It could become the next vaccine-based approach targeting PCSK9 (proprotein convertase subtilisin/kexin type 9 serine protease) to enter clinical trials.

    Feb 6, 2024

  • Greenphire Acquires Clincierge

    Clinical Research News | Yesterday, Greenphire, an innovator in clinical trials software, announced the acquisition of Clincierge, a premier provider of concierge travel and logistics support for patients participating in clinical trials.

    Feb 2, 2024

  • Smartwatch Could Reduce Fallout From False-Positive AFib Readouts

    Clinical Research News | A clinical-grade smartwatch does a good job of detecting possible atrial fibrillation (AFib), which could fill the need for a noninvasive option for monitoring patients for more than 30 days. Current available electrocardiography (ECG) technologies, such as Holter monitors and wearable event recorders, are both more time-limited and resource-intensive.

    Feb 1, 2024

  • Illumina Ventures Labs Now Operational, Personalized Medicine Coalition Releases 2024 Plans, Imagine Pharma Forms the Imagine Pharma Foundation, Collaborations, More

    Diagnostics World | Illumina Ventures Labs is now operational and finalizing agreements with several startup companies; the Personalized Medicine Coalition has released their Strategic Plan for Advancing Personalized Medicine in 2024; Imagine Pharma announced the formation of The Imagine Pharma Foundation, a private not for profit charitable organization dedicated to advancing metabolic research to significantly impact the lives of those affected by diabetes, with a particular emphasis on serving veterans; several collaborations and partnerships have been formed to tackle trials, studies, and research; more.

    Jan 31, 2024

  • Follow the Money: Most Extensive Liver Cirrhosis Study Funded, Expanded Biomedical Research Program, Antibody Development, More

    Clinical Research News | Newcastle University, University of Edinburgh, and Boehringer Ingelheim have received funding to begin the most extensive clinical study into liver cirrhosis ever; the University of New England has received an award from the National Institutes of Health to support an Institutional Development Award Center of Biomedical Research Excellence to be named the UNE Center for Cell Signaling Research; Oxitope Pharma and Arxx Therapeutics have merged to form Calluna Pharma Inc. (Calluna) and intend to work on a pipeline of selective antibodies that target inflammatory and fibrotic indications; more.

    Jan 30, 2024